Navigation Links
Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
Date:1/29/2013

a surgical field without causing damage to the vessels. The study also showed a reduction in the time required to perform an anastomosis for beating heart surgery when using LeGoo. Time is critical to patient outcomes in these types of surgical interventions.

Important Safety Information
LeGoo should only be used by physicians properly trained in vascular occlusion techniques. LeGoo should not be used in patients with vascular anatomy or blood flow that precludes cannula placement or proper injection and control of LeGoo or in patients intolerant to vascular occlusion or where temporary vascular occlusion would be contraindicated. Do not inject LeGoo into a vessel that is not intended to be occluded. Always use the minimum volume of LeGoo required to achieve satisfactory occlusion. LeGoo dissolves naturally and re-application may be necessary to maintain temporary blood vessel occlusion. Excessive or prolonged vessel occlusion may result in increased ischemic risks to the patient. Adverse Events (AEs) in clinical studies with LeGoo are consistent with anticipated AEs for patients undergoing cardiovascular surgery. Additional safety and Adverse Event information for LeGoo are described in the Instructions for Use (IFU).

About Sanofi Biosurgery
Sanofi Biosurgery is a global strategic business unit of Sanofi. It develops and markets innovative, biologically based products for osteoarthritis relief, adhesion prevention, cartilage repair, and severe burn treatment. Sanofi Biosurgery's products include: Synvisc®, Synvisc-One™ (hylan G-F 20), Carticel® (autologous cultured chondrocytes), MACI® (Matrix-induced Autologous Chondrocyte Implantation), Seprafilm® and Epicel® (cultured epidermal autografts). Sanofi Biosurgery is committed to transforming disease management through innovative medical interventions.

About Sanofi
Sanofi, a global and diversified hea
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
2. Sanofi Donates $500,000 to Hurricane Sandy for Immediate and Long-Term Relief Efforts
3. Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
4. Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
5. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
6. Sanofi Pasteur to add 2D barcode to six more vaccines
7. Sanofi US Launches Collaborate Activate Innovation Challenge
8. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
9. New Website IVT Network Launches Today for Validation and Compliance Professionals
10. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
11. Sequent Medical, Inc. Launches VIA Microcatheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of Tokyo ... next-generation sequencing (NGS) gene panels, for blood cancers  ... new test, indicate favorable prognosis for patients with bone ... sees potential for developing companion diagnostics to guide treatment ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... 15 Concentra, the largest,occupational health care provider ... campaign to educate America,s workforce about the flu, ... it. The company expects to vaccinate,nearly 300,000 people ... in lost productivity. Concentra Medical Centers offers ...
... Patients with,mid-range coronary artery disease are more likely ... have repeat procedures if they get bypass,surgery rather than ... new report by the Agency for Healthcare Research and ... Services. The analysis drew on 23 randomized controlled ...
Cached Medicine Technology:Concentra Offers Flu Vaccines to Keep America Working 2Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease 2Surgery More Likely Than Angioplasty to Relieve Pain for Patients With Coronary Artery Disease 3
(Date:7/24/2014)... 24, 2014 Just as fitness and ... consider their own financial and marketing strength to be ... campaigns to the next level by using the most ... IVR, Voice Broadcast, Call Tracking and SMS texting ... rate, text messages are quickly become integral in marketing ...
(Date:7/24/2014)... July 24, 2014 CarePoint Health ... in hematology and oncology, Dr. Hitendra Upadhyaya, has ... system welcomes Dr. Upadhyaya to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
(Date:7/24/2014)... News) -- Drinking caffeine may worsen the hot flashes ... as they go through menopause, new survey data suggests. ... that limiting caffeine intake may be useful for those ... sweats," said researcher Dr. Stephanie Faubion, director of the ... Minn. But caffeine -- a stimulant found in ...
(Date:7/24/2014)... Hospital and the University of Tennessee Health Science Center ... drug shown to safely reduce the viral load and ... respiratory syncytial virus (RSV). RSV is the most common ... in the United States and worldwide. , The ... John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab has been ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:RSV research breakthrough to help infected children 2
... ... - Gross margin expanded to 32.4 percent from ... Health management segment revenue grew 25 percent, - Net earnings: ... Nov. 3 Health Fitness,Corporation (NYSE Alternext US: FIT), a leading provider ...
... Held on Thursday November 6 at 8:30,a.m., NEW ... Board: VION) today announced financial,results for the three-month and ... a net loss of $6.8 million, or $0.92 per ... to a net loss,of $9.0 million, or $1.33 per ...
... neck, government study finds , , MONDAY, Nov. 3 (HealthDay ... with human papillomavirus (HPV) occurred in 38 states and ... officials reported Monday. , HPV is a group of ... than 30 of which can be sexually transmitted. Most ...
... A recent study conducted by researchers at Georgia ... demonstrate that administration of preemptive morphine prior to a ... of pain in adult rodents. These studies have ... administered to neonates prior to surgery. Infant rodents that ...
... Center at the University of California, San Diego (UCSD) ... at revving up the immune system to combat a ... therapy is being offered to patients with chronic lymphocytic ... resistant to initial treatment or harbors a particular chromosomal ...
... Revenue for the third quarter 2008 increases 32% to $16.0 million. - Heart ... surgical ablation products revenue grows 21.7%. ... Company raises lower end of its 2008 revenue guidance to $65 - $66 ... ...
Cached Medicine News:Health News:HealthFitness Announces 2008 Third Quarter Results 2Health News:HealthFitness Announces 2008 Third Quarter Results 3Health News:HealthFitness Announces 2008 Third Quarter Results 4Health News:HealthFitness Announces 2008 Third Quarter Results 5Health News:HealthFitness Announces 2008 Third Quarter Results 6Health News:HealthFitness Announces 2008 Third Quarter Results 7Health News:HealthFitness Announces 2008 Third Quarter Results 8Health News:HealthFitness Announces 2008 Third Quarter Results 9Health News:HealthFitness Announces 2008 Third Quarter Results 10Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 2Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 3Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 4Health News:Vion Reports 2008 Third Quarter and Nine-Month Results 5Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:GSU study first to confirm long-term benefits of morphine treatment in infants 2Health News:Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients 2Health News:ATS Medical Announces Third Quarter Results 2Health News:ATS Medical Announces Third Quarter Results 3Health News:ATS Medical Announces Third Quarter Results 4Health News:ATS Medical Announces Third Quarter Results 5Health News:ATS Medical Announces Third Quarter Results 6Health News:ATS Medical Announces Third Quarter Results 7Health News:ATS Medical Announces Third Quarter Results 8
... Designed To Hold & Support A Dropping Lens ... & Phacoemulsification To ,Continue. Can ... Of A Cyclodialysis Spatula To Reach Into ... Salvage Lens Fragments With One Instrument. ...
... Are Available In Two Models: One Is Direct ... Jaws Close. The Other Model Is Reverse ... Compressed The Jaws Open., ,The Forceps Are 22g, ... Through A 1.1mm Incision. These Forceps Allow The ...
... Designed To Dial An Exact Extension Of ... Maximum Visibility, With Titanium Handle & Spring. ... In Tissue, And Can Also Be Dialed ... Autoclaveable, Made In The USA, Handle Guaranteed ...
... The 0.1mm Pierce Tip Opening ... Flap, Without The Need For A Separate Cystotome. ... Grasping Positions Without Elevating The Incision.,The Distal Jaws ... Blades Help To Prevent Inadvertent Pick Up Of ...
Medicine Products: